[go: up one dir, main page]

AR024703A1 - Benzazepinonas y quinazolinas - Google Patents

Benzazepinonas y quinazolinas

Info

Publication number
AR024703A1
AR024703A1 ARP000103542A ARP000103542A AR024703A1 AR 024703 A1 AR024703 A1 AR 024703A1 AR P000103542 A ARP000103542 A AR P000103542A AR P000103542 A ARP000103542 A AR P000103542A AR 024703 A1 AR024703 A1 AR 024703A1
Authority
AR
Argentina
Prior art keywords
cell
well
quinazolinas
benzazepinonas
dhesive
Prior art date
Application number
ARP000103542A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR024703A1 publication Critical patent/AR024703A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
    • C07D239/96—Two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
    • C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
    • C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D267/14—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Los compuestos de la formula (1) así como también las sales y ésteres de los mismos que pueden utilizarse farmacéuticamente, donde R1, R2, X, Y, Z y ptienen el significado que se proporciona en la reivindicacion 1, inhiben la union de las proteínasa dhesivas a la superficie de diferentes tipos de células y,de acuerdo con ello, influye en las interacciones célula-célula y célula-matriz. Se los puede utilizar en la forma de preparaciones farmacéuticas para eltratamiento o la prevencion deneoplasm as, metástasis tumoral, desarrollo tumoral, osteoporosis, enfermedad de Paget, retinopatía diabética, degeneracionmacular, restenosis posterior a una intervencion vascular, psoriasis, artritis, fibrosis e insuficiencia renal así comotambién para la infeccion causada porvirus, bacterias u hongos.
ARP000103542A 1999-07-13 2000-07-11 Benzazepinonas y quinazolinas AR024703A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99113708 1999-07-13

Publications (1)

Publication Number Publication Date
AR024703A1 true AR024703A1 (es) 2002-10-23

Family

ID=8238595

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000103542A AR024703A1 (es) 1999-07-13 2000-07-11 Benzazepinonas y quinazolinas

Country Status (4)

Country Link
US (1) US6506744B1 (es)
AR (1) AR024703A1 (es)
AU (1) AU5826100A (es)
WO (1) WO2001004103A1 (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000066106A2 (en) 1999-04-30 2000-11-09 The Regents Of The University Of Michigan Use of benzodiazepines for treating autoimmune diseases induced by apoptosis
US7276348B2 (en) * 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
US7144880B2 (en) 1999-04-30 2006-12-05 Regents Of The University Of Michigan Compositions relating to novel compounds and targets thereof
US20050113460A1 (en) * 1999-04-30 2005-05-26 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20040176358A1 (en) * 1999-04-30 2004-09-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
US20060025388A1 (en) 1999-04-30 2006-02-02 Glick Gary D Compositions and methods relating to novel compounds and targets thereof
US20030119029A1 (en) * 1999-04-30 2003-06-26 Regents Of The University Of Michigan Compositions and methods relating to novel benzodiazepine compounds and targets thereof
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines
IL161692A0 (en) 2001-11-13 2004-09-27 Dimensional Pharm Inc 14-benzodiazepine derivatives and pharmaceutical compositions containing the same
DE60333937D1 (de) 2002-05-23 2010-10-07 Novartis Vaccines & Diagnostic Substituierte quinazolinone verbindungen
JP4619795B2 (ja) * 2002-12-31 2011-01-26 バーテックス ファーマシューティカルズ インコーポレイテッド ホスファターゼのインヒビター
US7439249B2 (en) * 2002-12-31 2008-10-21 Vertex Pharmaceuticals Incorporated Inhibitors of phosphatases
US20040142950A1 (en) * 2003-01-17 2004-07-22 Bunker Amy Mae Amide and ester matrix metalloproteinase inhibitors
WO2004112793A1 (en) 2003-05-23 2004-12-29 Chiron Corporation Guanidino-substituted quinazolinone compounds as mc4-r agonists
US20050272723A1 (en) * 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20060052369A1 (en) * 2004-09-07 2006-03-09 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2006074358A1 (en) * 2005-01-03 2006-07-13 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
WO2007053193A2 (en) * 2005-06-01 2007-05-10 The Regents Of The University Of Michigan Unsolvated benzodiazepine compositions and methods
US20070105844A1 (en) * 2005-10-26 2007-05-10 Regents Of The University Of Michigan Therapeutic compositions and methods
AU2006308655B2 (en) 2005-11-01 2010-09-23 The Regents Of The University Of Michigan Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties
JP5302012B2 (ja) * 2006-03-08 2013-10-02 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤
US7759338B2 (en) * 2006-04-27 2010-07-20 The Regents Of The University Of Michigan Soluble 1,4 benzodiazepine compounds and stable salts thereof
CA2659549C (en) 2006-06-09 2013-07-30 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
CA2783589A1 (en) 2007-03-09 2008-09-18 The Regents Of The University Of Michigan Compositions and methods relating to novel compounds and targets thereof
ES2614498T3 (es) 2007-09-14 2017-05-31 The Regents Of The University Of Michigan Inhibidores de ATPasa F1F0 y métodos relacionados
UA99839C2 (ru) 2007-11-06 2012-10-10 Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган Бензодиазепиноновые соединения, применяемые при лечении кожных состояний
JP5567573B2 (ja) 2008-09-11 2014-08-06 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン アリールグアニジンｆ１ｆ０−ａｔｐアーゼ阻害剤およびそれと関連する方法
WO2010121164A2 (en) 2009-04-17 2010-10-21 The Regents Of The University Of Michigan 1,4-benzodiazepinone compounds and their use in treating cancer
EP2470020A4 (en) 2009-09-18 2013-03-13 Univ Michigan BENZODIAZEPINONE COMPOUNDS AND TREATMENT METHODS THEREWITH
JP5856064B2 (ja) 2009-11-17 2016-02-09 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン 治療特性を有する１，４−ベンゾジアゼピン−２，５−ジオンおよび関連化合物
US9126978B2 (en) 2009-11-17 2015-09-08 The Regents Of The University Of Michigan 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties
JP6164610B2 (ja) * 2013-08-26 2017-07-19 国立大学法人東京農工大学 アミノ酸イソニトリル骨格を有する水中付着生物の防汚剤
WO2016019588A1 (en) * 2014-08-08 2016-02-11 The Broad Institute, Inc. Oxacazone compounds to treat clostridium difficile
JP2020509082A (ja) * 2017-02-10 2020-03-26 セレックス・オンコロジー・イノヴェーションズ・リミテッド がんの治療及び転移の抑制
CN111995576A (zh) * 2020-08-31 2020-11-27 三峡大学 多取代含氮杂环化合物的制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3497164B2 (ja) * 1991-06-28 2004-02-16 スミスクライン・ビーチャム・コーポレイション 二環式フィブリノーゲン拮抗薬
US5250679A (en) * 1991-10-18 1993-10-05 Genentech, Inc. Nonpeptidyl platelet aggregation inhibitors having specificity for the GPIIb III.sub. receptor
IT1254884B (it) * 1992-04-16 1995-10-11 Italfarmaco Spa Benzossazinoni e benzotiazinoni ad attivita' cardiovascolare
US5877278A (en) * 1992-09-24 1999-03-02 Chiron Corporation Synthesis of N-substituted oligomers
US5493020A (en) * 1993-07-29 1996-02-20 Genentech, Inc. Tricyclic inhibitors of the GPIIb IIIa receptor
AU1354097A (en) * 1995-12-29 1997-07-28 Smithkline Beecham Corporation Vitronectin receptor antagonists
WO1998004247A1 (en) * 1996-07-25 1998-02-05 Biogen, Inc. Cell adhesion inhibitors
ATE297904T1 (de) * 1997-04-15 2005-07-15 Genentech Inc Halo-alkoxycarbonylverbindungen
US6100282A (en) 1998-01-02 2000-08-08 Hoffman-La Roche Inc. Thiazole derivatives
EP0928790B1 (en) 1998-01-02 2003-03-05 F. Hoffmann-La Roche Ag Thiazole derivatives
AU5826100A (en) 1999-07-13 2001-01-30 F. Hoffmann-La Roche Ag Benzazepinones and quinazolines

Also Published As

Publication number Publication date
US6506744B1 (en) 2003-01-14
WO2001004103A1 (en) 2001-01-18
AU5826100A (en) 2001-01-30

Similar Documents

Publication Publication Date Title
AR024703A1 (es) Benzazepinonas y quinazolinas
ES2193471T3 (es) Derivados de tiazol.
BR0111457A (pt) Derivados de acilfeniluréia, processos para a sua preparação e sua aplicação como medicamentos
GT200000183A (es) Aminoacidos biciclicos como agentes farmaceuticos.
BRPI0112986B8 (pt) compostos azabicíclicos, processo para a sua preparação, bem como composições farmacêuticas compreendendo os ditos compostos
MXPA05012799A (es) Compuestos triheterociclicos, composiciones y metodos para tratar cancer o enfermedades virales.
BR0203644A (pt) Derivados heteroarìlicos dissubstituìdos com ácido como inibidores de metaloproteinase de matriz
NZ580226A (en) Dimer compounds as inhibitors of iap
BR0015477A (pt) Soluções contendo epinastina
BRPI0512139A (pt) derivados tetraidro-2h-isoquinolin-1-ona substituìdos, método para sua produção e uso do mesmo como medicamento
BRPI0516454A (pt) compostos, processo para a preparação de um composto, composição farmacêutica que o compreende, sua utilização, método para o tratamento e profilaxia de enfermidades, e de diabetes do tipo ii
ATE524181T1 (de) Verwendung von 1,4-bis (3-aminoalkyl) piperazin- derivaten bei der behandlung von neurodegenerativen erkrankungen
BRPI0416005A (pt) tiazolidinonas, na preparação e utilização como medicamento
AR023058A1 (es) Derivados del tiazol, un procedimiento para su obtencion, composiciones farmaceuticas que los comprenden y el empleo de los mismos para la preparacion demedicamentos
MEP54208A (en) Medicaments containing steroids and a novel anticholinesterase drug
AR022542A1 (es) Derivados de piperidina y piperazina
BR0016780A (pt) Derivados de piperazina substituìdos, preparação dos mesmos e seu uso como medicamentos
BR0316500A (pt) N-alquinil-2-(fenóxi substituìdas)alquilamidas e seu uso como fungicidas
ES2176895T3 (es) Derivados de tiazol.
ECSP993185A (es) Derivados de tiazol
ECSP982811A (es) Derivados de tiazol
SE0402507D0 (sv) Medicinsk lösning, förfarande för framställning och användning därav
ECSP982810A (es) Derivados de tiazol
BR0010525A (pt) cido 1-ciclo-hexeno-1-carboxìlico e 1-ciclo-hexeno-1carboxilatos como inibidores de neuraminidase
BR0307469A (pt) Derivados de fenilglicina solúveis em água